drugset / Trial / NCT03787251
A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib
RandomizedParallel-groupOpen-labelTreatment
Summary
A study of second-line treatment of postoperative recurrence and metastasis of esophageal squamous cell carcinoma after chemotherapy with apatinib mesylate
Timeline
- Start
- 2019-01-01
- Primary completion
- 2020-12-31
- Completion
- 2021-12-31
Outcome
Outcome not reported
Stopped (Enrollment): “In China, apatinib has been approved as an indication drug for esophageal squamous cell carcinoma, which makes it very difficult for our clinical trial to enroll patients. We regret that we failed to implement the design as planned.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Docetaxel | Small molecule | 60 mg/m2 | — |
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | — |
| Comparator | Irinotecan | Small molecule | 150 mg/m2 | — |
| Comparator | Irinotecan | Small molecule | 180 mg/m2 | — |
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |
| Subject | Rivoceranib | Small molecule | 750 mg | Oral |